Newsletter | April 9, 2020

04.09.20 -- Biosimilars & Value-Based Care: What To Watch

 
Featured Editorial
How Biosimilars, Biobetters Fit Into Value-Based Healthcare
 
By Anna Rose Welch, editor, Biosimilar Development

As the buck falls on physicians and healthcare systems to better control the cost of care, I wanted to hear from Dr. Chadi Nabhan about the value-based care models he’s been watching and how biosimilars (and biobetters) could fit into the overarching goals of these arrangements.

The 4 Stages Of Drug Delivery Device Evolution: An Inhaler Case Study
 
By Valerie Phillips, Michael Noble, and Mark Humphries, PA Consulting

To illustrate how delivery device development is evolving in practice, we will use the example of respiratory inhalers. This is a well-established treatment modality, with mature technology solutions available, but one where you can envisage a number of future changes enabled by technology. 

Industry Insights
Are Your Biologics At Risk For Protein Aggregation? Part 3
Article | By Martin Gonzalez, Ph.D., Pfizer CentreOne Contract Manufacturing

The main culprit of a failing biologics drug is usually a flawed formulation. Selecting the right formulation is a complex task. In many cases, the challenge of optimizing a formulation’s ingredients becomes finding just the right balance. This article explores some of the chief components of biologics formulations.

Scale-Up Of CHO Cell Fed-Batch Cultures In HyClone ActiPro Medium Supplemented With Cell Boost 7a And 7b
Application Note | GE Healthcare Life Sciences

The most widely used cell lines for biopharmaceutical production of therapeutic proteins originate from CHO cells. This application note compares cell growth and recombinant protein production of multiple Chinese hamster ovary (CHO) cell clones when cultured in HyClone ActiPro basal medium and Cell Boost 7a and 7b feeding supplements.

Solutions
Biacore Insight Evaluation Software
GE Healthcare Life Sciences
Connect With Biosimilar Development:
      Twitter